|
XPHYTO THERAPEUTICS CORP.
USA: XPHYF | Canada: XPHY | Germany: 4XT
Last Price: 2.49 | Website | SEC Filings | Latest News
This week's New Alert on XPHYF certainly did not disappoint as the Street is finally waking up to it's ONCE-IN-A-LIFETIME Potential!
Yesterday saw this Biotech play surge to highs of 2.72 from our 2.24 Alert - representing up to 21% GAINS *so far* on All-Time RECORD VOLUME! AND IT'S JUST GETTING STARTED XPHYF closed the day UP 11%, breaching significant technical barriers and further establishing it's BULLISH uptrend...
 XPHYF is still cheap under $3 as it nearins "Blue Skies Territory" with no upper chart resistance + a potentially IMMINENT "GOLDEN CROSS" of the 50 Day Moving Average through the 200 Day.
As mentioned yesterday, a Golden Cross is known as the crme de la crme of Bullish Indicators!
And lets not forget that Investing.com currently gives XPHYF it's Top Rating of "STRONG BUY" + Barchart.com currently rates this a "BUY" which just means we've got plenty of room to grow...
So what could set this current rally into the stratosphere?
How about some MASSIVE BREAKING NEWS regarding the company's potentially REVOLUTIONARY 25 Minute COVID-19 PCR Test?!?
| XPhyto European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test VANCOUVER, BC / February 16, 2021 / XPhyto Therapeutics Corp., and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce that all actions and procedures required for its European regulatory application for the rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR Test System ("Covid-ID Lab") have been completed.
3a expects ISO 13485 approval as a medical device manufacturer by late February and European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for Covid-ID Lab by early March.
Covid-ID Lab was designed to be a rapid, accurate and robust test system with reduced operating costs and increased convenience and portability. Initial manufacturing is planned for Germany with additional capacity in other jurisdictions to follow. The sales launch in Europe is targeted for April 2021. XPhyto is currently in discussions with potential distribution and wholesale partners in Europe and the Middle East. The Company will provide further information and updates in due course.
"We are very pleased with the team's swift development progress," said Hugh Rogers, CEO & Director of XPhyto. "Our goal was to create the fastest and most portable COVID-19 PCR test on the market. We are confident in our prospects for an expedited approval and look forward to commercial launch in short order." [READ MORE] |
So as we said...European APPROVAL could be **ANY DAY NOW**!!!
And if that doesnt get the Big Dawg's on the Street's attention...I dont' know what willl!!
WHY XPHYF??
XPhyto Therapeutics Corp. (XPHYF) is a Bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids.
XPHYF's exclusive Strategic Partnership with 3a-Diagnostics GmbH who are together developing a re-engineered PCR diagnostic exam to make it what could be the world’s FASTEST and most portable Covid-19 test, with results delivered in as little as 25 minutes.
Best of all, XPHYF's test is so portable it can be done with minimal equipment and training in a clinic, a hospital, a car, nursing home etc.
So on one hand, XPHYF could very well change the world....but they can also seriously CAPITALIZE on it! IMPORTANT: While excitement about a 25-minute Covid-19 test seems justifiable, it’s equally
important to clearly acknowledge this: that via its partner, 3a, what XPHYF has developed is in no way to be confused with a vaccine, cure, therapy, treatment, or containment strategy. |
XPHYF - A DIVERSE BIOSCIENCE PLAY
XPHYF is also aiming to combat epilepsy, chronic pain, and more using CBD with proprietary sublingual thin film technology through it's subsidiary Vektor Pharma as well as research into Psychedelics for usage in mental health and psychotherapy.
We'll get to more of that as the week progresses....
THE BOTTOM LINE
If you missed XPHYF yesterday....fear not - TODAY COULD BE EVEN BIGGERwith Massive News now being digested by the market!
As noted above, European Regulatory Approval for it's 25 MINUTE Rapid COVID PCR tests could come ANY DAY NOW and Wall Street is still BARELY aware of it!!
With a surging BULLISH chart, multiple BUY Ratings, and so much more, XPHYF is now officially *in play* and must be at the top of your radar!!
|